He emphasizes the importance of this first guideline from ASCO on anal squamous cell carcinoma for both clinicians and patients with stage I-III anal cancer, and ongoing research the panel is looking ...

While 2015 was marked by great announcements in the field of immunotherapy – particularly in melanoma and non-small cell lung cancer (NSCLC), this year’s American Society of Clinical Oncology ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced data from its ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel, first-in-class biologic therapy ...

The battle against rectal cancer has entered an extraordinary new phase with the advent of immunotherapy, offering hope to ...

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III ...

ALX Oncology Holdings Inc. announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN – Research Report) today and set a price target of $11.00.Stay ...